Loading…
← CockpitCompetitor Analysis › JAZZ Jazz Pharmaceuticals Public Limited CompanyOpen in the cockpit ↗

Jazz Pharmaceuticals Public Limited CompanyJAZZCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Specialty biopharma selling narcolepsy drugs (Xywav, Xyrem), epilepsy drug Epidiolex, and oncology treatments.

Momentum strong 72
Mkt cap
$15.9B
US dollars, full cap
Free float
96%
of shares outstanding
$/day
$178M
20-day average traded
Fwd P/E
9.3×
forward earnings
ROIC−WACC
+6.6 pp
WACC 6.6%
Hurdle
-15 pp
Req g minus delivered
Next earnings
104 days
2 Mar 2027
Close · USD$247.77
1D+2.9%
1W-0.2%
1M+15.9%
3M-0.4%
6M+3.7%
YTD+45.8%
1Y+45.7%
ATR %3.0%
Beta0.65
52w lowhigh7.0% off high

What Jazz Pharmaceuticals Public does

Specialty biopharma selling narcolepsy drugs (Xywav, Xyrem), epilepsy drug Epidiolex, and oncology treatments.

Sells its sleep drugs through a single central pharmacy under a safety program required for the active ingredient, sodium oxybate. Buying GW Pharmaceuticals in 2021 added Epidiolex, and Zepzelca is licensed from PharmaMar. The company is based in Ireland.

Products and services

  • Xywav/Xyrem (narcolepsy)
  • Epidiolex (epilepsy)
  • Zepzelca (oncology)

Customers

  • Sleep-medicine specialists
  • Neurologists
  • Oncologists

Where it sits in the supply chain

  • Pharmaceuticals
  • Branded biopharma
  • Neuroscience and oncology

What could go right

  • Xywav share gains over older Xyrem
  • Epidiolex international expansion

What could go wrong

  • Generic oxybate competition risk
  • Oncology portfolio smaller/less differentiated than peers

Moat: narrow (IP / patents, regulatory licence). Controlled-substance distribution expertise and patents on its oxybate franchise limit direct generic competition.

Headquarters: Dublin, Ireland · Founded: 2003 · Employees: 2,890

Named competitors

Jazz Pharmaceuticals Public at a glance

Size Jazz Pharmaceuticals Public (JAZZ) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $15.9B, the 569th largest of 3,085 United States companies the cockpit tracks. Shares closed at $247.77 on 18 Nov 2026.

Performance Over six months the shares gained 3.7%, against +4.6% for the median peer and -2.2% for the United States market (cap-weighted) — 9th lowest of 21 in its peer set.

Growth Revenue grew 13.5% over the last twelve months (peer median +18.9%); the operating margin is 24.8% (peer median 21.3%).

Valuation It trades at 9.3× forward earnings against a peer median of 28.0× (cheapest of 20).

Price implies For today's price to make sense, revenue must grow about -3% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -15 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 6.6 points above its cost of capital (6.6% WACC).

Credit Jazz Pharmaceuticals Public has 1 bond outstanding ($1.00B).

Short interest Short interest is 9.0% of the free float (30 Oct 2026).

Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026Peer median 105JAZZ 103
Six months, rebased to 100: Jazz Pharmaceuticals Public against the median of its 20 peers (local-currency closes).

Jazz Pharmaceuticals Public financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$4.72B$4.27B$4.07B$3.83B$3.66B
Revenue growth—+5%+6%+5%—
Gross profit$3.52B$3.11B$3.00B$2.79B$2.52B
EBITDA$1.89B$1.45B$1.39B$1.30B$1.35B
Net income$206M-$356M$560M$415M-$224M
Free cash flow$1.62B$1.30B$1.36B$1.07B$1.24B
Capital expenditure$201M$167M$38.1M$24.0M$54.0M
Total debt$5.64B$5.43B$6.17B$5.80B$5.82B

Quarterly statements and history in the cockpit →

Jazz Pharmaceuticals Public competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%+60%-10%0%+10%SOBIORNAVEXELASND6446000538688506IPNTORNTPHARMLAURUSLABS18016990ZYDUSLIFEALNYDRREDDY1177REC600436MANKINDJAZZ6-month return →1-month return →
Up and to the right = strong over both horizons. Jazz Pharmaceuticals Public is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×500×1,000×SOBIORNAVEXELASND64464507LAURUSLABS18016990ZYDUSLIFEALNYDRREDDY600436JAZZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Jazz Pharmaceuticals Public is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%+150%0%50%100%150%SOBIORNAVASND64464507TORNTPHARMLAURUSLABS18016990ALNYDRREDDY600436JAZZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Jazz Pharmaceuticals Public is the large dot.

Jazz Pharmaceuticals Public competitors and peer comparison

Head to head with its named competitors (JAZZ vs HRMY vs ALKS vs AXSM)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Jazz Pharmaceuticals Public JAZZ$15.9B+4%+13%25%9.3×-2.8%
Harmony Biosciences HRMY$1.94B+6%+20%22%8.6×-10.5%
Alkermes Public ALKS$7.87B+27%+15%5%n/a32.5%
Axsome Therapeutics AXSM$7.05B-42%+54%-19%77.1×n/a
Takeda Pharmaceutical 4502.T$69.8B+30%+6%18%51.0×3.7%
SKBP 326030.KS$5.03B-16%+37%38%21.5×-4.4%

How Jazz Pharmaceuticals Public compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Jazz Pharmaceuticals Public against its 20 peers (data as of 18 Nov 2026)
MeasureJAZZPeer medianRank in peer set
1-month return+15.9%+5.7%2nd highest of 21
6-month return+3.7%+4.6%9th lowest of 21
Distance from 52-week high-7.0%-7.0%11th highest of 21
Revenue growth (TTM)+13.5%+18.9%7th lowest of 21
Operating margin24.8%21.3%9th highest of 21
Forward P/E9.3×28.0×cheapest of 20
Growth the price implies (Req g, 7 yrs)-2.8%6.4%5th least demanding of 19
Growth delivered (Del g)+12.5%+12.3%10th highest of 19
Hurdle (Req g minus delivered)-15.3 pp-11.2 pp6th least demanding of 19
ROIC minus cost of capital+6.6 pp+7.9 pp10th lowest of 21
EV / EBITDA9.9×18.5×3rd cheapest of 17
Net debt / EBITDA1.5×-0.1×3rd most indebted of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Jazz Pharmaceuticals Public JAZZUnited States$15.9B+4%+13%25%9.3×-2.8%+12.5%
Swedish Orphan Biovitrum SOBI.STSweden$16.1B+6%+15%30%24.1×-2.1%+13.1%
Orion ORNAV.HEFinland$15.7B+41%+34%38%23.6×-6.2%+11.7%
Exelixis EXELUnited States$16.7B+37%+9%40%17.7×-3.8%+18.6%
Ascendis Pharma A/S ASNDUnited States$16.9B+12%+94%18%28.0×19.2%+152.4%
PharmaEssentia 6446.TWTaiwan$15.0B+67%+78%40%31.9×23.7%+94.8%
Yunnan Baiyao 000538.SZChina$15.0B+11%+5%11%18.3×-0.2%+4.7%
Sichuan Biokin Pharmaceutical 688506.SSChina$14.9B-7%+14%-43%n/an/an/a
Ipsen IPN.PAFrance$14.8B+1%+14%30%10.8×-6.7%+7.2%
Shionogi & 4507.TJapan$17.6B+3%+46%29%11.8×0.2%+11.0%
Torrent Pharmaceuticals TORNTPHARM.NSIndia$18.8B+3%+42%22%70.2×37.6%+11.3%
Laurus Labs LAURUSLABS.NSIndia$13.4B+73%+23%24%76.4×51.2%+7.3%
Innovent Biologics 1801.HKHong Kong$18.9B+4%+43%17%52.3×11.6%+26.8%
Sichuan Kelun-Biotech Biopharmaceutical 6990.HKHong Kong$13.0B-1%+44%-38%1,176.1×55.3%+33.6%
Zydus Lifesciences ZYDUSLIFE.NSIndia$12.8B+18%+24%17%30.0×n/an/a
Alnylam Pharmaceuticals ALNYUnited States$20.0B-50%+56%20%21.2×0.5%+49.8%
Dr. Reddy's Laboratories DRREDDY.NSIndia$12.5B+5%-4%9%32.0×30.7%+12.1%
Sbp 1177.HKHong Kong$12.2B+5%+15%30%17.5×-5.7%+5.4%
Recordati REC.MIItaly$12.0B+3%+8%30%16.6×1.1%+12.6%
Zhangzhou Pientzehuang Pharmaceutical 600436.SSChina$11.6B-4%-19%19%40.7×24.9%+6.8%
Mankind Pharma MANKIND.NSIndia$11.6B+5%+13%21%44.4×28.6%+18.1%

Jazz Pharmaceuticals Public bonds and credit

Jazz Pharmaceuticals Public has 1 bond outstanding with $1.00B face value.

Every bond, yield and spread in the cockpit →

Questions

Who are Jazz Pharmaceuticals Public's main competitors?
Named competitors: Avadel Pharmaceuticals (private or unlisted), Harmony Biosciences (HRMY), UCB (private or unlisted), Alkermes (ALKS), Axsome Therapeutics (AXSM), Takeda Pharmaceutical (4502.T). The cockpit's measured peer set (industry) also includes Swedish Orphan Biovitrum (SOBI.ST), Orion (ORNAV.HE), Exelixis (EXEL), Ascendis Pharma A/S (ASND), PharmaEssentia (6446.TW), Yunnan Baiyao (000538.SZ).
Is Jazz Pharmaceuticals Public expensive compared with its peers?
On forward p/e it trades at 9.3× against a peer median of 28.0×, cheapest of 20 in its peer set. For today's price to make sense, revenue must grow about -3% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -15 pp: the price already allows for a slowdown.
How has Jazz Pharmaceuticals Public stock performed?
Over six months to 18 Nov 2026 the shares returned +3.7% against +4.6% for the median peer; over one year +45.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.